SNGX OTC/bb. PR. Staging.

1/4/12 FDA to Initiate Program Evaluating OrbeShieldTM as a Therapy for Gastrointestinal Acute radiation syndrome (GI-ARS).

Soligenix has previously received Orphan Drug Designation for oral BDP for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.